{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:26Z","timestamp":1793228306469,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rectal cancer treatment has transformed in recent years, with neoadjuvant treatment (NT) and total neoadjuvant treatment (TNT) aiming to enhance pathological responses. This pioneering study in our country delves into rectal cancer management, offering crucial insights by examining pathological outcomes in patients treated with the NT and TNT approach, shaping the evolving landscape.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective-cohort study spanning January 2017 to December 2022 at a tertiary care hospital in Pakistan, ethical approval was obtained to examine outcomes of two treatments. Patients were divided into TNT (chemoradiation and pre-surgery 5 FU-based chemotherapy) and NT (chemoradiation, surgery, and subsequent 5 FU-based chemotherapy). The primary end-point was response rates\u2014no response, pathological complete response (pCR), near complete response (near CR), and partial response (PR). The Chi-Square Test for Independence assessed the association between treatment response and type (TNT or NT). Data analysis used STATA MP 64; significance was set at <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 for all two-tailed tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed 77 patients, 60 underwent standard neoadjuvant chemoradiation, and 17 followed the total neoadjuvant approach. Predominantly male, most were\u2009&gt;\u200965 with ECOG 0\u20131. The TNT group showed higher response rates (76% vs 62%, <jats:italic>p<\/jats:italic>\u2009=\u20090.039), with 40.38% achieving pCR. In the overall population, pCR and near-CR were similar (27.2% vs 26%), while PR were 14%. Treatment characteristics correlated significantly with chemotherapy type, concurrent chemoradiation, LVI, PNI, and T, N, M staging (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Median overall survival was not reached, and mean survival was 89.1\u00a0months (CI: 95.0 to 83.3). Side effects varied, with notable differences in neuropathy, diarrhea, oral mucositis, and thrombocytopenia between NT and TNT groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study adds to evidence favoring neoadjuvant approaches in managing rectal cancer in pakistan. Demonstrating a favorable pcr rate, ongoing research with extended follow-up is essential, given the dynamic landscape of rectal cancer treatment for improved patient outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12241-6","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:01:52Z","timestamp":1713243712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes"],"prefix":"10.1186","volume":"24","author":[{"given":"Misbah Younus","family":"Soomro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib Raza","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujjawal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawazish","family":"Zehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Rameez","family":"Samar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Moosajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Abdul","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"6","key":"12241_CR1","first-page":"625","volume":"33","author":"A Ikram","year":"2023","unstructured":"Ikram A, Pervez S, Khadim MT, Sohaib M, Uddin H, Badar F, et al. National Cancer Registry of Pakistan: First Comprehensive Report of Cancer Statistics 2015\u20132019. J Coll Physicians Surg Pak. 2023;33(6):625\u201332.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"3","key":"12241_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12241_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7314\/APJCP.2016.17.1.89","volume":"17","author":"A Akbar","year":"2016","unstructured":"Akbar A, Bhatti AB, Niazi SK, Syed AA, Khattak S, Raza SH, et al. Impact of Time Interval Between Chemoradiation and Surgery on Pathological Complete Response and Survival in Rectal Cancer. Asian Pac J Cancer Prev. 2016;17(1):89\u201393.","journal-title":"Asian Pac J Cancer Prev"},{"key":"12241_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/GO.20.00596","volume":"7","author":"MA Mansha","year":"2021","unstructured":"Mansha MA, Waheed A, Sadaf T, Rashid A, Irfan N, Chaudry SJ. Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan. JCO Global Oncology. 2021;7:790\u20136.","journal-title":"JCO Global Oncology"},{"issue":"6","key":"12241_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579\u201388.","journal-title":"Lancet Oncol"},{"key":"12241_CR6","doi-asserted-by":"publisher","first-page":"1067036","DOI":"10.3389\/fimmu.2022.1067036","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shen L, Wan J, Zhang H, Wu R, Wang J, et al. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: a new era for anal preservation. Front Immunol. 2022;13:1067036.","journal-title":"Front Immunol"},{"issue":"4","key":"12241_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0360-3016(99)00486-1","volume":"46","author":"M Mohiuddin","year":"2000","unstructured":"Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DE, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete Response. Int J Radiat Oncol Biol Phys. 2000;46(4):883\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12241_CR8","unstructured":"Macrae FA, Bendell J, Tanabe KK, Savarese D, Grover S. Clinical presentation, diagnosis, and staging of colorectal cancer. 2023. UpToDate Retrieved from https:\/\/www.uptodate.com\/contents\/clinical-presentation-diagnosis-and-stagingof-colorectal-cancer. Accessed 11 Nov 2023."},{"issue":"11","key":"12241_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114\u201323.","journal-title":"N Engl J Med"},{"issue":"28","key":"12241_CR10","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F, Bouch\u00e9 O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3\u20134 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620\u20135.","journal-title":"J Clin Oncol"},{"issue":"16","key":"12241_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926\u201333.","journal-title":"J Clin Oncol"},{"key":"12241_CR12","doi-asserted-by":"publisher","first-page":"6756859","DOI":"10.1155\/2016\/6756859","volume":"2016","author":"XJ Wang","year":"2016","unstructured":"Wang XJ, Zheng ZR, Chi P, Lin HM, Lu XR, Huang Y. Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:6756859.","journal-title":"Gastroenterol Res Pract"},{"issue":"9","key":"12241_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","volume":"11","author":"M Maas","year":"2010","unstructured":"Maas M, Nelemans PJ, Valentini V, Das P, R\u00f6del C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835\u201344.","journal-title":"Lancet Oncol"},{"issue":"8","key":"12241_CR14","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","volume":"26","author":"C Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial\u2020. Ann Oncol. 2015;26(8):1722\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"12241_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomized, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"23","key":"12241_CR16","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12241_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2559.2005.02176.x","volume":"47","author":"R Ryan","year":"2005","unstructured":"Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O\u2019Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141\u20136.","journal-title":"Histopathology"},{"issue":"25","key":"12241_CR18","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363\u201376.","journal-title":"N Engl J Med"},{"key":"12241_CR19","doi-asserted-by":"crossref","unstructured":"Patel S, Kazi M, Desouza AL, Sukumar V, Gori J, Bal M, Saklani A. Outcomes of rectal cancer patients with a positive pathological circumferential resection margin. Langenbecks Arch Surg. 2022;1:1\u20139.","DOI":"10.1007\/s00423-021-02392-6"},{"issue":"39","key":"12241_CR20","doi-asserted-by":"publisher","first-page":"e30687","DOI":"10.1097\/MD.0000000000030687","volume":"101","author":"T Chen","year":"2022","unstructured":"Chen T, Wang M, Cheng X, Wang Y, Jiang Y, Fang X, Xiao H. The complementary role of lymphovascular invasion and perineural invasion in the TNM staging process of rectal cancer. Medicine. 2022;101(39):e30687.","journal-title":"Medicine"},{"issue":"15","key":"12241_CR21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, Liu WY, Chen SL, Li S, Lu NN, Cai Y. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681.","journal-title":"J Clin Oncol"},{"issue":"8924","key":"12241_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(94)92206-3","volume":"344","author":"IJ Adam","year":"1994","unstructured":"Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344(8924):707\u201311.","journal-title":"Lancet"},{"issue":"10","key":"12241_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215\u201323.","journal-title":"Br J Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12241-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12241-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12241-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:02:04Z","timestamp":1713243724000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12241-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12241"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12241-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"13 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Aga Khan University Hospital Ethical Review Committee (AKUH-ERC) approved our study.Due to the retrospective nature of the study, the need for informed consent was waived by Ethical Review Committee of Aga Khan University Hospital, Karachi, Pakistan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}